Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States.* This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes worldwide. In the U.S., the updated software for the FreeStyle Libre 3 Plus sensor integration is preloaded on all new t:slim X2 pump shipments, and is also available to all eligible t:slim X2 pump users through a software update.† The Company plans to launch early-access programs for the integrated technologies internationally before the end of the year, with scaling commercial availability to follow in 2026.

With this integration, we expand the benefits of greater control to more people living with diabetes worldwide with our AID system that is easy to start, use, and personalize," said John Sheridan, president and chief executive officer. "It combines Control-IQ+, our most advanced algorithm ever, together with the benefits of Abbott's latest CGM sensor on our tested and trusted t:slim X2 insulin pump."

The FreeStyle Libre 3 Plus sensor is the world's smallest CGM available today.1 It transmits automatic glucose readings every minute directly to the pump and offers an extended 15-day wear time. Control-IQ+ technology is Tandem's newest advanced hybrid closed-loop algorithm, which adjusts insulin every five minutes based on predicted glucose values. It is also the only system featuring AutoBolus,‡ which automatically calculates and delivers a correction bolus, helping reduce the impact of missed meal boluses and easing the day-to-day burden of diabetes management.